Here is the synopsis of our sample research paper on WTO 2001-PUBLIC HEALTH DECLARATION AND TRIPS. Have the paper e-mailed to you 24/7/365.
Essay / Research Paper Abstract
This 20 page paper addresses the issues of patents and intellectual property protection as defined by the World Trade Organization at its 2001 meeting in Doha, Qater. The paper analyzes WTO's TRIPS and Public Health Declaration, an attempt to define when patents on medications can be overridden in the event of a health crisis in a developing nation. Bibliography lists 11 sources.
Page Count:
20 pages (~225 words per page)
File: D0_MTwtopub.rtf
Buy This Term Paper »
Unformatted sample text from the term paper:
of a dilemma. Wilting under criticism that the AIDS "cocktails" are too expensive, drug companies have come back with the comment that the research and manufacturer of AIDS drugs is
expensive, and that theyre businesses who need to make money, not non-profit organizations. It is one concern when this argument is
between drug companies and U.S. citizens, many of whom have health insurance that can pay for the drugs (although there are just as many who dont, which opens another area
of discussion). It is quite another issue when those afflicted with AIDS and other epidemic diseases live in poor and/or developing nations with no access to health insurance and no
way to afford the life-saving drugs. In an attempt to make these medications more affordable to their residents, developing nations have been
trying, for years, to override patents on various drugs so that the medication can be purchased and/or manufactured at a less expensive cost than that incurred when buying directly from
a pharmaceutical firm that has the patent on a particular drug. The most recent challenge between "Big Pharm," the pharmaceutical companies in
the United States and elsewhere, and developing nations came about at the November 2001, World Trade Organization, which took place in Doha, Qatar. It was believed that an intellectual property
agreement already in place was not enough to assist developing countries as they attempt to treat epidemic diseases. This paper will examine the adoption of the agreement by the World
Trade Organization, as well as discuss the position of the Pharmaceutical Research and Manufacturers of Americas (PhRMA) position in the need for quality drugs in developing nations and in the
...